Published in Rev Urol on January 01, 2005
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res (2008) 1.26
Evaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic strips. BMC Urol (2015) 0.80
Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer. Am J Nucl Med Mol Imaging (2017) 0.76
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
Biology of prostate-specific antigen. J Clin Oncol (2003) 2.44
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol (2001) 2.15
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2004) 1.91
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Prostate specific antigen only progression of prostate cancer. J Urol (2000) 1.77
Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome. J Urol (2004) 1.76
Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol (2000) 1.66
Current status of local salvage therapies following radiation failure for prostate cancer. J Urol (2005) 1.57
Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest (1987) 1.55
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer (2002) 1.55
Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol (2000) 1.20
Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract (2004) 1.20
The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol (1989) 1.18
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology (2000) 0.99
Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol (2000) 0.96
Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys (2001) 0.96
Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl (1999) 0.91
Expression of prostate specific antigen in male breast cancer. J Clin Pathol (2005) 0.90
Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol (1993) 0.90
A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol (1994) 0.86
Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int (2004) 0.86
Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. Appl Immunohistochem Mol Morphol (2000) 0.85
Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer (1997) 0.85
Salvage radical prostatectomy: refinement of an effective procedure. Semin Radiat Oncol (2003) 0.82
Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol (2002) 0.80
Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Williston Park) (1998) 0.79
PSA after radiation for prostate cancer. Oncology (Williston Park) (2004) 0.77
Genomic research and prostate cancer: what does it offer us? BJU Int (2005) 0.77
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol (2003) 2.40
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res (2007) 2.34
Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol (2003) 2.10
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol (2003) 2.06
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2004) 1.91
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol (2008) 1.91
Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol (2007) 1.71
ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene (2002) 1.55
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol (2008) 1.46
Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35
PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res (2003) 1.25
Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res (2006) 1.22
The burden of prostate cancer in Asian nations. J Carcinog (2012) 1.19
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology (2012) 1.16
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem (2008) 1.11
Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res (2010) 1.09
The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate (2009) 1.06
The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int (2006) 1.04
Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 1.03
Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. Int J Oncol (2007) 1.03
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep (2002) 1.02
Prostate cancer in men less than the age of 50: a comparison of race and outcomes. Urology (2011) 1.02
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology (2009) 0.97
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology (2006) 0.97
Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer (2011) 0.96
Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res (2005) 0.94
Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev (2010) 0.93
Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles. Int J Oncol (2007) 0.93
Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. Exp Cell Res (2007) 0.91
Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol (2010) 0.91
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis. J Zhejiang Univ Sci B (2007) 0.87
Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res (2008) 0.87
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol (2005) 0.87
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol (2004) 0.86
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology (2011) 0.85
Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India. J Cancer (2013) 0.85
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. Int J Radiat Oncol Biol Phys (2003) 0.85
Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol (2009) 0.85
Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy. Cancer (2006) 0.84
Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 0.83
Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology (2007) 0.83
Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol (2005) 0.83
Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. Urol Oncol (2011) 0.83
The design and implementation of a multidisciplinary prostate cancer clinic. Urol Nurs (2007) 0.83
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol (2005) 0.83
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res (2003) 0.82
ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity. Monoclon Antib Immunodiagn Immunother (2014) 0.81
The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol (2006) 0.80
Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment. Urol Oncol (2012) 0.80
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. Urol Oncol (2002) 0.79
Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment. Rev Urol (2010) 0.79
Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res (2005) 0.79
Prostate cancer marker panel with single cell sensitivity in urine. Prostate (2015) 0.79
A novel neoplastic primary tumor-derived human prostate epithelial cell line. Int J Oncol (2003) 0.79
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg (2009) 0.78
Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. Pathol Int (2010) 0.78
Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005. J Natl Med Assoc (2011) 0.77
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology (2004) 0.77
Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol (2004) 0.77
Sarcoidosis of the prostate. J Clin Pathol (2007) 0.76
Perioperative complications of radical retropubic prostatectomy. Clin Genitourin Cancer (2005) 0.76
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol (2004) 0.76
Success and failure of single-modality treatment for early prostate cancer. Rev Urol (2004) 0.75
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer (2007) 0.75
Storm over screening for prostate specific antigen. Give men facts on prostate cancer. BMJ (2002) 0.75
Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present. Urol Oncol (2009) 0.75
Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology. Urology (2009) 0.75
An assessment of the virtual conversations method for prostate cancer patient education. Urol Nurs (2007) 0.75
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol (2004) 0.75